Webber, Andrea L.
Merck & Co., Inc., Rahway, NJ, USA (United States)
3 papers on CoChatORCID 0000-0003-2463-0878
Most cited papers
- Verified
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 2,479
- Verified
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 2,301
- Verified
The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
Cazanave, S., Podtelezhnikov, A., Jensen, K., Seneshaw, M., Kumar, D. P., Min, H.-K., Santhekadur, P. K., Banini, B., Mauro, A. G., M. Oseini, A., et al. (2017) · Scientific Reports
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 66
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free